Altimmune, Inc. (NASDAQ:ALT) Short Interest Update

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 20,370,000 shares, an increase of 14.9% from the March 31st total of 17,730,000 shares. Based on an average daily trading volume, of 4,690,000 shares, the short-interest ratio is presently 4.3 days.

Institutional Investors Weigh In On Altimmune

Several institutional investors have recently modified their holdings of ALT. Timelo Investment Management Inc. grew its holdings in Altimmune by 2,597.0% during the 4th quarter. Timelo Investment Management Inc. now owns 809,095 shares of the company's stock valued at $9,102,000 after purchasing an additional 779,095 shares during the last quarter. GSA Capital Partners LLP raised its holdings in shares of Altimmune by 153.1% in the third quarter. GSA Capital Partners LLP now owns 445,868 shares of the company's stock worth $1,159,000 after buying an additional 269,676 shares during the period. Lighthouse Investment Partners LLC purchased a new stake in shares of Altimmune in the fourth quarter worth approximately $4,493,000. Gerber LLC lifted its stake in shares of Altimmune by 10.2% during the 1st quarter. Gerber LLC now owns 281,778 shares of the company's stock worth $2,868,000 after acquiring an additional 26,000 shares during the last quarter. Finally, Dark Forest Capital Management LP boosted its holdings in Altimmune by 13.4% during the 3rd quarter. Dark Forest Capital Management LP now owns 230,353 shares of the company's stock valued at $599,000 after acquiring an additional 27,210 shares during the period. 78.05% of the stock is owned by institutional investors.

Altimmune Stock Down 11.9 %

NASDAQ ALT traded down $0.87 on Monday, reaching $6.40. The company had a trading volume of 4,920,032 shares, compared to its average volume of 5,310,766. The stock has a market capitalization of $453.34 million, a PE ratio of -3.88 and a beta of 0.05. Altimmune has a 12 month low of $2.09 and a 12 month high of $14.84. The firm's 50 day moving average price is $9.24 and its 200 day moving average price is $7.61.

Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings data on Wednesday, March 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.02. The business had revenue of $0.04 million for the quarter. Altimmune had a negative return on equity of 44.77% and a negative net margin of 20,780.75%. On average, research analysts expect that Altimmune will post -1.52 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Guggenheim cut shares of Altimmune from a "buy" rating to a "neutral" rating in a research note on Monday. The Goldman Sachs Group initiated coverage on shares of Altimmune in a research report on Wednesday, January 24th. They set a "neutral" rating and a $13.00 price objective for the company. HC Wainwright decreased their target price on Altimmune from $15.00 to $12.00 and set a "buy" rating on the stock in a report on Monday, April 1st. Finally, B. Riley reiterated a "buy" rating and set a $20.00 target price on shares of Altimmune in a research report on Thursday, March 28th.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.